Valentina Andreoli

Dr. Valentina Andreoli

Scienze Medico-Veterinarie, University of Parma, Parma, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Animals
Verified
Journal Article
Open access
PDF file
PPPaola Palagiano
Paola Palagiano
LGLisa Graziano
Lisa Graziano
WSWalter Scarabello
Walter Scarabello
PBPriscilla Berni
Priscilla Berni
VAValentina Andreoli
Valentina Andreoli
SGStefano Grolli
Stefano Grolli
Aural hematoma is a common pathological condition in veterinary practice with a high incidence rate in dogs. Drainage, corticosteroid injections, and surgical approaches represent the common treatments in these clinical cases. However, surgery leaves visible signs and is usually correlated with recurrence, scars, and deformation of the treated pinna. For this reason, more effective and less invasive methods have been proposed over the years. Platelet-Rich Plasma (PRP) is one of the most promising options due to its pro-regenerative properties and capability to modulate the inflammatory state. The present work reports 12 cases of canine aural hematoma treated with PRP. The PRP treatment was combined with an ultrasound evaluation of the pinna to detect and treat all involved septa. The results show that relatively large volumes (2 mL) of PRP associated with an ultrasound guide are safe and efficacious in the treatment of canine aural hematoma requiring a maximum of two infiltrations, both in acute and chronic conditions. All the patients recovered their normal ear thickness (compared with the controlateral one) without relapses, averaging 38.5 days from their first treatment (10–90 days; SD: 24.7). The key role of PRP combined with a tailored diagnosis process carried out by the veterinarian, which included using an ultrasound system and the proper bandage, suggests that this approach may represent a valid alternative to surgery and corticosteroids.

Verified
Journal Article
Open access
PDF file
VAValentina Andreoli
Valentina Andreoli
PBPriscilla Berni
Priscilla Berni
VCVirna Conti
Virna Conti
RRRoberto Ramoni
Roberto Ramoni
Giuseppina BasiniGiuseppina Basini
Giuseppina Basini
SGStefano Grolli
Stefano Grolli
Mesenchymal Stromal Cells (MSCs)-based therapies are rapidly gaining interest in veterinary medicine. Cellular therapy represents a new challenge for practitioners and requires precise coordination between the cell processing laboratory and the veterinary clinic. Cryopreservation is the best method to provide fast, in-time, and long-distance delivery of cells for therapeutic applications. However, potentially toxic cryoprotectants and xenobiotic products make the direct administration of cells impracticable for patients. Alternatively, the cells may be resuspended in a ready-to-use vehicle and shipped to the veterinary clinic. In this study, two nutrient-poor vehicles (physiologic saline and ringer lactate solutions) and two nutrient-rich vehicles (the releasate derived from autologous Platelet Poor Plasma and Platelet Rich Plasma) were tested on adipose tissue-derived canine MSCs (AD-MSCs). AD-MSCs stored for 2, 4, or 24 h in the different media were compared regarding mortality, metabolic activity, and replicative capacity. Furthermore, antioxidant activity and the pattern of expression of genes related to AD-MSCs function were performed following 24 h of storage. The results showed that all the different vehicles preserve cell vitality and replication following short-term storage. In long-term storage, the vehicle and cell density affect cell vitality, proliferation, and gene expression (CCL-2, CXCR-4, and TSG-6). Nutrient-rich vehicles seem better suited to preserve cell functionalities in this contest.

15 December 2022 in Animals
Verified
Journal Article
Open access
PDF file
Giuseppina BasiniGiuseppina Basini
Giuseppina Basini
FGFrancesca Grasselli
Francesca Grasselli
FQFausto Quintavalla
Fausto Quintavalla
SBSimona Bussolati
Simona Bussolati
VAValentina Andreoli
Valentina Andreoli
SBSimone Bertini
Simone Bertini
Triclosan is a chlorinated biphenolic with a broad spectrum of antiseptic activities used in cosmetics and hygiene products. Continuous exposure can lead to absorption and bioaccumulation of this substance with harmful health effects. In fact, previous studies have shown that Triclosan acts as an endocrine-disrupting chemical on reproductive organs, with consequent negative effects on reproductive physiology. Therefore, to assess potential adverse impacts on fertility, we tested Triclosan on swine granulosa cells, a model of endocrine reproductive cells. We examined its effects on the main features of granulosa cell functions such as cell growth (BrdU incorporation and ATP production) and steroidogenesis (17-β estradiol and progesterone secretion). Moreover, since oxidant–antioxidant balance plays a pivotal role in follicular function, redox status markers (superoxide, hydrogen peroxide and nitric oxide production, enzymatic and non-enzymatic scavenging activity) were studied. Our results show that Triclosan significantly inhibits cell growth (p < 0.001), steroidogenesis (p < 0.001), superoxide and nitric oxide production (p < 0.001), while it increases (p < 0.05) enzymatic defense systems. Collectively, these data suggest a disruption of the main granulosa cell functions, i.e., proliferation and hormone production, as well as an imbalance in redox status. On these bases, we can speculate that Triclosan would impair granulosa cell functions, thus exerting negative effects on reproductive function. Further studies are needed to explore lower Triclosan concentrations and to unravel its mechanisms of action at gene level.

16 June 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
PBPriscilla Berni
Priscilla Berni
MBMaurizio Del Bue
Maurizio Del Bue
VCVirna Conti
Virna Conti
VAValentina Andreoli
Valentina Andreoli
RRRoberto Ramoni
Roberto Ramoni
SGStefano Grolli
Stefano Grolli
Most in vivo studies on MSC-secretome for osteoarthritis (OA) have relied on animal models, using products lacking pharmaceutical quality, not formulated for clinical use, and insufficiently characterized, limiting knowledge of its effectiveness. This study reports veterinary clinical trials on dogs and horses with spontaneous OA: in dogs (26 subjects), the trial is randomized, double-blinded, and controlled; in horses, 5 clinical cases were treated for safety assessment. Treatment consisted of hyaluronic acid with either lyosecretome - a freeze-dried, injectable MSC-secretome obtained through standardized GMP manufacturing - or mannitol, the lyosecretome excipient (control), intrarticularly administered. Patients underwent clinical evaluations and orthopedic assessments over an 80-day follow-up; dog-owner feedback was collected through questionnaires. Lyosecretome doesn't induce systemic adverse responses. In dogs, improvement following treatment - significant in favor of lyosecretome - was observed, especially in reducing lameness; although it did not demonstrate significant pain reduction, patients were significantly more likely to walk, play, and move easily after exercise. Proteomic investigation supported these efficacy findings, revealing lyosecretome proteins involved in inhibiting protease and hyaluronidase, as well as in regulating immune response and inflammation, and those associated with cartilage regeneration and antioxidant activity. These results support the beneficial effect of MSC-secretome on joint disorders and offer insights that may be relevant to human patients, given the similarities in OA pathophysiology between humans and dogs or horses.

Verified
Journal Article
Open access
PDF file
PBPriscilla Berni
Priscilla Berni
VAValentina Andreoli
Valentina Andreoli
VCVirna Conti
Virna Conti
RRRoberto Ramoni
Roberto Ramoni
Giuseppina BasiniGiuseppina Basini
Giuseppina Basini
SGStefano Grolli
Stefano Grolli
Therapies based on mesenchymal stromal cells (MSCs) have become one of the most significant advancements in veterinary regenerative medicine. The isolation of MSCs is usually performed by enzymatic digestion and requires variable times for cell expansion. In addition, these procedures need to be performed in specialized laboratory facilities. An alternative approach to in vitro-expanded MSC therapy is the use of microfragmented adipose tissue (microfat), which is a rich source of cells and growth factors from the stromal vascular fraction. Recent clinical studies support its safety and efficacy in the treatment of musculoskeletal disorders and wound healing. The aim of the present work was to characterize the microfragmented adipose tissue obtained by a new mechanical device, which provides sterile tissue that is ready for use in the clinic by the veterinarian, avoiding the need for specialized laboratory facilities. Microfat-derived MSCs were compared with enzymatically isolated MSCs in terms of their phenotypic characterization, growth rate and differentiation potential. Conditioned medium derived from microfat culture was evaluated for its ability to promote MSC vitality. No differences were observed between MSCs obtained through mechanical fragmentation and those derived from collagenase digestion of adipose tissue, suggesting that the device could serve as a practical source of microfragmented adipose tissue for use in veterinary clinics.

31 December 2025 in Viruses
Verified
Journal Article
Open access
PDF file
SLSofia Lopez
Sofia Lopez
IÁIgnacio Álvarez
Ignacio Álvarez
SDSantiago Delgado
Santiago Delgado
VAValentina Andreoli
Valentina Andreoli
NLNaiara Urrutia Luna
Naiara Urrutia Luna
AVAndrea Elizabeth Verna
Andrea Elizabeth Verna
Bovine gammaherpesvirus 4 (BoGHV-4) is an opportunistic uterine pathogen whose reactivation is associated with postpartum inflammation and bacterial lipopolysaccharide (LPS). Platelet-rich plasma (PRP) is a regenerative biotherapeutic capable of modulating inflammatory responses, although its effects may vary depending on BoGHV4 genotype. In this study, primary bovine endometrial cells (BECs) were cultured in medium containing 10% PRP instead of fetal bovine serum, infected with two genetically divergent BoGHV-4 isolates (07-435, genotype 3; 10-154, genotype 2), and subsequently stimulated with bacterial lipopolysaccharide (LPS, 100 ng/mL). Expression of the viral immediate-early gene IE-2 and host immune genes (TLR4, TNF-α, CXCL8, and IFN-γ) were quantified by RT-qPCR from 4 to 48 h after stimulation. Isolate 07-435 induced a sustained activation of IE-2 and gradual cytokine upregulation, while isolate 10-154 elicited an early but transient inflammatory response followed by gene downregulation. PRP did not modify the strain-specific patterns of viral and inflammatory gene expression but established a common inflammatory baseline, whereas the magnitude and temporal profile of the response continued to be dictated by the viral genotype. These findings indicate that BoGHV-4 genotypic diversity remained the main determinant of response intensity and duration, supporting PRP as a context-dependent rather than a universal antiviral modulator.